<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03667872</url>
  </required_header>
  <id_info>
    <org_study_id>PINS-029</org_study_id>
    <nct_id>NCT03667872</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of DBS in Patients With Treatment-Resistant Depression</brief_title>
  <official_title>Efficacy and Safety of MRI Compatible and Long-term LFP Recordable Deep Brain Stimulation in Patients With Treatment-Resistant Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Pins Medical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Pins Medical Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The habenula (Hb) is an ancient structure, located at the center of the dorsal diencephalic
      conduction system, a pathway involved in linking forebrain to midbrain regions. An increasing
      number of studies indicated that the lateral habeluna (LHb) is overactivity during depressive
      behaviors in rats, where it could drive the changes in midbrain monoamine neurotransmitter
      linked to depression. However, the efficiency and mechanism of deep brain stimulation (DBS)
      of the LHb and/or its major afferent bundle (i.e., stria medullaris thalami) could treat
      treatment-resistant major depression (TRD) is still unclear. This research will investigate
      the effectiveness and mechanism of bilateral MRI Compatible and Long-term LFP Recordable DBS
      to habenula and/or its major afferent bundle for treatment TRD patients.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 15, 2019</start_date>
  <completion_date type="Anticipated">June 18, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 18, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Hamilton Anxiety Scale</measure>
    <time_frame>Baseline（preoperative）,3 months, 6 months, 12months</time_frame>
    <description>Change in the Hamilton Anxiety Scale after the DBS on</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Treatment Resistant Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MRI compatible and LFP recordable implantable stimulator</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bilateral implantation of DBS system to Habeluna</intervention_name>
    <description>Bilateral implantation of MRI compatible and LFP recordable DBS system to Habeluna</description>
    <arm_group_label>Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-70 years old;

          -  DSM-IV diagnosis of Major depression disorder of psychiatrists;

          -  More than 3 year's history of depression and failure to respond to a minimum of three
             different antidepressant treatments;

          -  Failure or intolerance or unwilling of an adequate course of electroconvulsive therapy
             (ECT) during any episode;

          -  HAMD-17≥20;

          -  GAF≤50；

          -  Capacity to provide informed consent (understanding of the study purpose and methods);

        Exclusion Criteria:

          -  Obvious medical and psychiatric comorbidities;

          -  Alcohol or substance abuse/dependence within 12 months;

          -  Antisocial personality disorder, dementia, current tic disorder;

          -  Subject has a history of 2 or more suicide attempts &lt; 12 months prior to the screening
             testing;

          -  Pregnancy and/or lactation;

          -  There are contraindications for DBS surgery and chronic stimulation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhiyan Wang</last_name>
    <phone>010-60736388</phone>
    <email>wzyann@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Habenula DBS</name>
      <address>
        <city>Shenzhen</city>
        <state>Shenzhen</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiaodong Cai</last_name>
      <phone>0755-83366388</phone>
    </contact>
    <contact_backup>
      <last_name>Yingli Zhang</last_name>
      <phone>0755-25533524</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>September 10, 2018</study_first_submitted>
  <study_first_submitted_qc>September 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2018</study_first_posted>
  <last_update_submitted>December 24, 2018</last_update_submitted>
  <last_update_submitted_qc>December 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Deep Brain Stimulation</keyword>
  <keyword>Habenula</keyword>
  <keyword>Functional magnetic resonance imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

